Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Sapena, Victor|||0000-0003-4379-6486
  • Boix, Loreto|||0000-0002-6015-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Guedes, Cassia
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darnell, Anna
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Rimola, Jordi|||0000-0002-1814-4198
  • Forner, Alejandro|||0000-0002-9014-4950
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication, A Population-Based Cohort Study

  • Ríos, José|||0000-0002-0716-8784
  • Sapena, Victor|||0000-0003-4379-6486
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bruix, Jordi|||0000-0002-9826-0753
  • Forns, Xavier|||0000-0002-8188-1764
  • Morros, Rosa|||0000-0001-6752-8748
  • Reig, María|||0000-0002-5711-9534
  • Torres, Ferran|||0000-0002-7355-7913
  • Pontes García, Caridad|||0000-0002-3274-6048
Background and Objectives: Direct-acting antivirals (DAAs) offer a high rate of hepatitis C virus (HCV) eradication. However, concerns on the risk of cancer after HCV eradication remain. Our study aimed at quantifying the incidence of cancer in patients treated with anti-HCV therapies in Catalonia (Spain) and their matched controls. Methods: This was a population-based study using real-world data from the public healthcare system of Catalonia between 2012 and 2016. Propensity score matching was performed in patients with HCV infection treated with interferon-based therapy (IFN), sequential IFN and DAA (IFN+DAA), and DAA only (DAA) with concurrent controls. We estimated the annual incidence of overall cancer, hepatocellular carcinoma, and non-liver cancer of HCV-treated patients and their corresponding rate ratios. Results: The study included 11,656 HCV-treated patients and 49,545 controls. We found statistically significant increases in the rate of overall cancer for IFN+DAA-treated (rate ratio [RR] 1.77, 95% confidence interval [CI] 1.27-2.46) and DAA-treated patients (RR 1.90, 95% CI 1.66-2.19) and in the rate of HCC for IFN-treated (RR 1.50, 95% CI 1.02-2.22), IFN+DAA-treated (RR 3.89, 95% CI 2.26-6.69), and DAA-treated patients (RR 6.45, 95% CI 4.90-8.49) compared with their corresponding controls. Moreover, DAA-treated patients with cirrhosis showed an increased rate of overall cancer versus those without cirrhosis (RR 1.92, 95% CI 1.51-2.44). Conclusions: Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.